DR REDDYS LABORATORIES LTD
RDY evidence brief
What we can confirm
- BioSniper Score:
- 10.0 / 10
- Market Cap:
- $9.91B
- Lead Asset:
- abiraterone (Approved)
What it means
What to watch
Prepared research question
What matters most for RDY—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · RDY
Dr. Reddy's Laboratories Ltd (RDY) is a global pharmaceutical company specializing in generic drug manufacturing, with a pipeline of approved products including ticagrelor, vigabatrin, and zafirlukast, and a history of PDUFA dates for various drugs.
Key risk: Lack of pipeline depth
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Tracking 87 pipeline candidates · 157 FDA decisions for DR REDDYS LABORATORIES LTD.
Dr. Reddy's Laboratories Ltd (RDY) is a global pharmaceutical company specializing in generic drug manufacturing, with a pipeline of approved products including ticagrelor, vigabatrin, and zafirlukast, and a history of PDUFA dates for various drugs.
- Dr. Reddy's has a pipeline of approved generic drugs including ticagrelor, vigabatrin, and zafirlukast [pipeline].
- The company has a history of PDUFA dates for drugs such as morphine (2016-10-28), nystatin (2017-01-31), and butalbital (2017-12-27) [catalyst].
- Approved pipeline candidates include apixaban, bortezomib, and clopidogrel bisulfate [pipeline].
- The pipeline includes delivery vectors such as oral tablets and intravenous solutions for various drugs [pipeline].
What works
- Dr. Reddy's has a broad portfolio of approved generic drugs, indicating a strong track record in regulatory approvals [pipeline].
- The company has a history of multiple PDUFA dates, suggesting consistent engagement with the FDA for drug approvals [catalyst].
What to weigh
- The pipeline data provided is limited to approved drugs, with no information on drugs in earlier development stages, which may indicate a lack of near-term pipeline depth [pipeline].
- The catalyst timeline includes only historical PDUFA dates, with no recent or upcoming catalysts, potentially signaling a slowdown in new drug applications [catalyst].
From the filings
Quoted directly from source documents.
Dr. Reddy's has approved generic drugs in its pipeline.
“Pipeline Candidate: ticagrelor Generic Name: TICAGRELOR Phase: Approved Delivery Vector: ORAL TABLET”
The company has a history of PDUFA dates for various drugs.
“Catalyst Timeline: [2016-10-28] PDUFA: PDUFA: morphine [2017-01-31] PDUFA: PDUFA: nystatin”
Catalysts
Approved pipeline candidates include apixaban.
“Pipeline Candidate: apixaban Generic Name: APIXABAN Phase: Approved”
Catalyst timeline
- 2016-10-28 · PDUFA: morphine — This is a historical PDUFA date for morphine, indicating past regulatory activity.
- 2017-01-31 · PDUFA: nystatin — This is a historical PDUFA date for nystatin, indicating past regulatory activity.
- 2017-12-27 · PDUFA: butalbital — This is a historical PDUFA date for butalbital, indicating past regulatory activity.
- 2018-10-10 · PDUFA: aspirin — This is a historical PDUFA date for aspirin, indicating past regulatory activity.
Risks & what to watch (2)›
Key risks
- Lack of pipeline depth — Pipeline data shows only approved drugs, with no early-stage candidates, suggesting limited future innovation [pipeline].
- No recent catalysts — Catalyst timeline ends in 2023, with no upcoming PDUFA dates, indicating a potential gap in new drug applications [catalyst].
What to watch
- Monitor for any new PDUFA dates or regulatory filings to assess pipeline activity [catalyst].
- Watch for updates on the development of new generic drugs beyond the current approved list [pipeline].
Sources: Catalysts · Pipeline · Generated October 10, 2026 · How we verify sources →
Run DR REDDYS LABORATORIES LTD through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available DR REDDYS LABORATORIES LTD facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Approved
87 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
246
Total value held
$1.60B
| Holder | Shares | Value |
|---|---|---|
| robeco institutional asset management b.v. | 17,177,882 | $237.9M |
| blackrock, inc. | 11,587,127 | $160.5M |
| royal bank of canada | 9,984,082 | $138.3M |
| morgan stanley | 9,371,594 | $129.8M |
| aikya investment management ltd | 7,999,796 | $110.8M |
| renaissance technologies llc | 7,859,728 | $108.9M |
| dimensional fund advisors lp | 5,323,248 | $73.7M |
| jpmorgan chase & co | 4,371,378 | $58.8M |
| state street corp | 4,026,207 | $55.8M |
| bnp paribas financial markets | 3,183,971 | $44.1M |
Showing top 10 of 246 institutional holders of DR REDDYS LABORATORIES LTD. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 3.7%
- Days to cover
- 6.1
- Shares short
- 15,719,527
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
RDY short interestFrequently asked questions
What is the AI investment thesis for DR REDDYS LABORATORIES LTD?
Dr. Reddy's Laboratories Ltd (RDY) is a global pharmaceutical company specializing in generic drug manufacturing, with a pipeline of approved products including ticagrelor, vigabatrin, and zafirlukast, and a history of PDUFA dates for various drugs.
What is DR REDDYS LABORATORIES LTD's lead drug candidate?
DR REDDYS LABORATORIES LTD's most advanced tracked candidate is abiraterone (Approved).
Who is the CEO of DR REDDYS LABORATORIES LTD?
Mr. Erez Israeli M.B.A. is the chief executive officer of DR REDDYS LABORATORIES LTD (RDY).
Where is DR REDDYS LABORATORIES LTD headquartered?
DR REDDYS LABORATORIES LTD (RDY) is headquartered in Hyderabad, India.
What therapeutic areas does DR REDDYS LABORATORIES LTD focus on?
DR REDDYS LABORATORIES LTD develops therapies across Oncology, Respiratory, Pain.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.